# EDGAR Filing Document

**Accession Number:** 0001661059
**File Stem:** 0001558370-25-008789
**Filing Date:** 2025-6
**Character Count:** 7301
**Document Hash:** 8d932fa4963c609f54539c8f2869e8f4
**Contains OCR:** False
**Source Format:** 

## Filing Content

## Filing Summary
**0001558370-25-008789.hdr.sgml**: 20250623

**ACCESSION NUMBER**: 0001558370-25-008789

**CONFORMED SUBMISSION TYPE**: 8-K

**PUBLIC DOCUMENT COUNT**: 13

**CONFORMED PERIOD OF REPORT**: 20250620

**ITEM INFORMATION**: Submission of Matters to a Vote of Security Holders

**FILED AS OF DATE**: 20250623

**DATE AS OF CHANGE**: 20250623

**FILER**: 

**COMPANY DATA:**
- **COMPANY CONFORMED NAME:** NextCure, Inc.
- **CENTRAL INDEX KEY:** 0001661059
- **STANDARD INDUSTRIAL CLASSIFICATION:** PHARMACEUTICAL PREPARATIONS [2834]
- **ORGANIZATION NAME:** 03 Life Sciences
- **EIN:** 475231247
- **STATE OF INCORPORATION:** DE
- **FISCAL YEAR END:** 1231

**FILING VALUES:**
- **FORM TYPE:** 8-K
- **SEC ACT:** 1934 Act
- **SEC FILE NUMBER:** 001-38905
- **FILM NUMBER:** 251063140

**BUSINESS ADDRESS:**
- **STREET 1:** 9000 VIRGINIA MANOR ROAD, SUITE 200
- **CITY:** BELTSVILLE
- **STATE:** MD
- **ZIP:** 20705
- **BUSINESS PHONE:** 240-399-4900

**MAIL ADDRESS:**
- **STREET 1:** 9000 VIRGINIA MANOR ROAD, SUITE 200
- **CITY:** BELTSVILLE
- **STATE:** MD
- **ZIP:** 20705

?xml version='1.0' encoding='ASCII'? NextCure, Inc._June 20, 2025

------

**UNITED STATESSECURITIES AND EXCHANGE COMMISSION**

**Washington, D.C. 20549**

**FORM 8-K**

**CURRENT REPORTPursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934**

Date of Report (Date of earliest event reported): June 20, 2025

**NextCure, Inc.**

(Exact name of registrant as specified in its charter)

---

| | | |
|:---|:---|:---|
| **Delaware**(State or other jurisdiction of incorporation) | **001-38905**(Commission File Number) | **47-5231247**(IRS Employer Identification No.) |

---

---

| | |
|:---|:---|
| **9000 Virginia Manor Road, Suite 200**<br>**Beltsville, Maryland** | **20705** |
| (Address of principal | (Zip Code) |
| executive offices) |  |

---

Registrant's telephone number, including area code: **(240) 399-4900**

(Former name or former address, if changed since last report.)

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

☐ Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

☐ Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

☐ Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

☐ Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Securities registered pursuant to Section 12(b) of the Act:

---

| | | |
|:---|:---|:---|
| &nbsp;&nbsp;**Title of each class** | &nbsp;&nbsp;**Trading Symbol(s)** | &nbsp;&nbsp;**Name of each exchange on which registered** |
| &nbsp;&nbsp;Common Stock, $0.001 par value per share | &nbsp;&nbsp;NXTC | &nbsp;&nbsp;Nasdaq Global Select Market |

---

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter). Emerging growth company ☐

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

------

**Item 5.07** **Submission of Matters to a Vote of Security Holders**

On June 20, 2025, the Company held its 2025 Annual Meeting of Stockholders (the "Annual Meeting"). At the Annual Meeting, the Company's stockholders: (i) elected the three Class III members of the Board of Directors (the "Board"), each to serve for a three-year term expiring at the Company's 2028 Annual Meeting of Stockholders and until such director's earlier death, resignation, or removal from the Board; (ii) ratified the appointment of Ernst & Young LLP as the Company's independent registered public accounting firm for the fiscal year ending December 31, 2025; (iii) approved, on an advisory basis, the compensation paid to the Company's named executive officers (the "say-on-pay vote"); (iv) approved, on an advisory basis, to hold a say-on-pay vote every year; and (v) approved an amendment to the Company's Amended and Restated Certificate of Incorporation to effect a reverse stock split, if and when determined by the Board (the "Reverse Split Proposal"). Because the Reverse Split Proposal was approved, the sixth proposal regarding adjournment of the Annual Meeting was rendered moot and was not presented. Set forth below are the voting results for each of the proposals voted upon by the Company's stockholders at the Annual Meeting.

*Proposal No. 1: Election of Class III Directors*

---

| | | | | |
|:---|:---|:---|:---|:---|
| &nbsp;&nbsp;**Nominee** | &nbsp;&nbsp;**For** | &nbsp;&nbsp;**Against** | &nbsp;&nbsp;**Abstain** | &nbsp;&nbsp;**Broker Non-Votes** |
| &nbsp;&nbsp;David Kabakoff, Ph.D. | &nbsp;&nbsp;8109613 | &nbsp;&nbsp;3641993 | &nbsp;&nbsp;501 | &nbsp;&nbsp;8450029 |
| &nbsp;&nbsp;Michael Richman | &nbsp;&nbsp;9090049 | &nbsp;&nbsp;2661491 | &nbsp;&nbsp;567 | &nbsp;&nbsp;8450029 |
| &nbsp;&nbsp;Stephen W. Webster | &nbsp;&nbsp;9034425 | &nbsp;&nbsp;2717181 | &nbsp;&nbsp;501 | &nbsp;&nbsp;8450029 |

---

*Proposal No. 2: Ratification of Appointment of Independent Registered Public Accounting Firm for the Fiscal Year Ending December 31, 2025*

---

| | | | | | | | |
|:---|:---|:---|:---|:---|:---|:---|:---|
| **For** | **For** | **Against** | **Against** | **Abstain** | **Abstain** | **Broker Non-Votes** | **Broker Non-Votes** |
|  | 18,767,121 |  | 1,434,513 |  | 502 |  | - |

---

*Proposal No. 3: Advisory Vote to Approve Executive Compensation*

---

| | | | | | | | |
|:---|:---|:---|:---|:---|:---|:---|:---|
| *0*<br>|  |  |  |  |  |  |  |
| **For** | **For** | **Against** | **Against** | **Abstain** | **Abstain** | **Broker Non-Votes** | **Broker Non-Votes** |
|  | 11,316,309 |  | 421,792 |  | 14,006 |  | 8,450,029 |

---

*Proposal No. 4: Advisory Vote to Approve the Frequency of Advisory Votes on Executive Compensation*

---

| | | | | | | | | |
|:---|:---|:---|:---|:---|:---|:---|:---|:---|
| *0*<br>|  |  |  |  |  |  |  |  |
| **1 Year** | **1 Year** | **2 Years** | **2 Years** | **3 Years** | **3 Years** | **Abstain** | **Abstain** | **Broker Non-Votes** |
|  | 11,664,330 |  | 2,631 |  | 43,161 |  | 41,985 | 8,450,029 |

---

*Proposal No. 5: The Reverse Split Proposal*

---

| | | | | | | | |
|:---|:---|:---|:---|:---|:---|:---|:---|
| *0*<br>|  |  |  |  |  |  |  |
| **For** | **For** | **Against** | **Against** | **Abstain** | **Abstain** | **Broker Non-Votes** | **Broker Non-Votes** |
|  | 18,166,577 |  | 2,028,946 |  | 6,613 |  | - |

---

**SIGNATURE**

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

---

| | | |
|:---|:---|:---|
| November<br>|  |  |
| Dated: June 23, 2025 | **NEXTCURE, INC.** | **NEXTCURE, INC.** |
|  | By:  | /s/ Steven P. Cobourn  |
|  | Name: | Steven P. Cobourn |
|  | Title: | Chief Financial Officer  |

---